Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
10 Health Care Stocks With Whale Alerts In Today's Session
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51
Piper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
Express News | Edgewise Therapeutics Inc : Piper Sandler Raises Target Price to $51 From $48
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)
Capricor Stock Rallies 20% on DMD Data Presentation Update
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Edgewise Therapeutics (EWTX) Gets a Buy From Truist Financial
Edgewise Therapeutics(EWTX.US) Officer Sells US$3.57 Million in Common Stock
$Edgewise Therapeutics(EWTX.US)$ Officer Carruthers R Michael sold 125.09K shares of common stock on Sep 20, 2024 at an average price of $28.5708 for a total value of $3.57 million.Source:
Edgewise Therapeutics CMO Sells $202k in Company Stock
Edgewise Therapeutics Executive Sells Over $1.2m in Stock
Edgewise Therapeutics General Counsel Sells Over $1.9m in Company Stock
Edgewise Therapeutics CFO Sells Over $3.5 Million in Company Stock
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Truist Financial analyst Srikripa Devarakonda maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and maintains the target price at $33.According to TipRanks data, the analyst has a
Form 144 | Edgewise Therapeutics(EWTX.US) Officer Proposes to Sell 3.57 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 20, $Edgewise Therapeutics(EWTX.US)$ Officer ROBERT MICHAEL CARRUTHERS intends to sell 125.09K shares of its common stock on Sep 20, with a total market value of
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Wedbush analyst Laura Chico maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and adjusts the target price from $31 to $44.According to TipRanks data, the analyst has a success rate of 52.
Edgewise Therapeutics Analyst Ratings